Free Trial

Etzer Darout Analyst Performance

Managing Director & Senior Biotechnology Analyst at BMO Capital Markets

Etzer Darout is a stock analyst at BMO Capital Markets in the medical sector, covering 16 publicly traded companies. Over the past year, Etzer Darout has issued 8 stock ratings, including and buy recommendations. While full access to Etzer Darout's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Etzer Darout's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
27 Last 5 Years
Buy Recommendations
77.78% 21 Buy Ratings
Companies Covered
16 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy77.8%21 ratings
Hold22.2%6 ratings
Sell0.0%0 ratings

Out of 27 total stock ratings issued by Etzer Darout at BMO Capital Markets, the majority (77.8%) have been Buy recommendations, followed by 22.2% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
93.8% of companies on NASDAQ
15 companies
NYSE
6.3% of companies on NYSE
1 company

Etzer Darout, an analyst at BMO Capital Markets, currently covers 16 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
16 companies
100.0%

Etzer Darout of BMO Capital Markets specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
9 companies
56.3%
PHARMACEUTICAL PREPARATIONS
4 companies
25.0%
MED - DRUGS
2 companies
12.5%
MED PRODUCTS
1 company
6.3%

Etzer Darout's Ratings History at BMO Capital Markets

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
9/2/2025Boost Price Target$6.19$13.00Buy
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
8/7/2025Lower Price Target$34.62$45.00Outperform
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
5/13/2025Lower Price Target$2.93$15.00Outperform
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
4/15/2025Boost Price Target$5.07$24.00Buy
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
4/4/2025Lower Price Target$3.26$9.00Buy
Arvinas, Inc. stock logo
ARVN
Arvinas
3/12/2025Set Price Target$8.51$20.00Outperform
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
3/11/2025Boost Price Target$105.35$143.00Outperform
Arvinas, Inc. stock logo
ARVN
Arvinas
2/12/2025Reiterated Rating$18.88$82.00Outperform